Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Alcestobart
LBL-007 · 2 trials · 4 indications
Percentage of participants whose best overall response (BOR) is complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.
| Arm | Type | Description |
|---|---|---|
| LBL-007 | EXPERIMENTAL | LBL-007 in combination with tislelizumab plus chemotherapy doublet. |
| Tislelizumab and Chemotherapy | ACTIVE_COMPARATOR | Tislelizumab plus chemotherapy doublet. |
| Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | EXPERIMENTAL | Participants received alcestobart low dose, tislelizumab, bevacizumab and capecitabine until disease progression, unacceptable toxicity, or withdrawal of consent. |
| Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | EXPERIMENTAL | Participants received alcestobart medium dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine | EXPERIMENTAL | Participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 2: Arm A:PD-L1-positive: Alcestobart High Dose +Tislelizumab + Bevacizumab +Fluoropyrimidine | EXPERIMENTAL | PD-L1 (programmed cell death protein ligand-1)-positive participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine | EXPERIMENTAL | PD-L1-positive participants received alcestobart high dose, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine | ACTIVE_COMPARATOR | PD-L1-positive participants received bevacizumab and fluoropyrimidine in combination with leucovorin or levoleucovorin (LV) until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine | EXPERIMENTAL | PD-L1-negative participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine | ACTIVE_COMPARATOR | PD-L1-negative participants received bevacizumab and fluoropyrimidine in combination with LV until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen). |
| Name | Type | Description |
|---|---|---|
| LBL-007 | DRUG | LBL-007 will be administered at a standard dose intravenously. |
| Tislelizumab | DRUG | Tislelizumab will be administered at a standard dose intravenously. |
| Chemotherapy Doublet | DRUG | Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously. |
| Alcestobart | DRUG | Administered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks |
| Bevacizumab or Bevacizumab biosimilar | DRUG | Administered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks. |
| Fluoropyrimidine (FP) | DRUG | Fluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks. |
Inclusion Criteria: * Able to provide written informed consent and can agree to comply with the study requirements. * Participants with metastatic ESCC or unresectable, locally advanced ESCC. * Histologically confirmed diagnosis of ESCC. * Can provide a tumor sample. * At least 1 measurable lesion ...
Top 20 of 39 competitors
LBL-007 is an investigational small molecule developed by BeOne Medicines Ltd. (ticker ONC). It is being studied in oncology as a LAG-3 targeted agent, both in esophageal cancer and in unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer. It is currently in Phase 2 clinical development.
LBL-007 is being evaluated for the treatment of esophageal cancer, including esophageal squamous cell carcinoma, and for unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer. It is an investigational therapy and is not approved for any indication.
LBL-007 targets LAG-3, a protein immune checkpoint receptor. By binding LAG-3, the drug is designed to modulate an inhibitory pathway that suppresses T cell activity. In clinical studies it is given in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy or bevacizumab plus fluoropyrimidine.
LBL-007 is developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company is running the clinical program for the asset across sites in China, South Korea, Taiwan, Thailand, the United States, Australia, and Puerto Rico.
LBL-007 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The Phase 2 study in esophageal squamous cell carcinoma has completed, while a Phase 1 colorectal cancer study remains active but is no longer recruiting.
LBL-007 has been studied in two registered trials. NCT06010303 is a completed Phase 2 study of LBL-007 plus tislelizumab and chemotherapy in unresectable locally advanced or metastatic esophageal squamous cell carcinoma, enrolling 118 participants. NCT05609370 is an active Phase 1 study in unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer, enrolling 113 participants.